Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Cladribine
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Cladribine
(Tablets)
Malignant disease and immunosuppression, Antimetabolites, 08.01.03
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local
BNF
Section
Cladribine
Cladribine
Immune System, Immune System Disorders And Transplantation, Multiple Sclerosis, Antineoplastic Drugs Antimetabolites
Cladribine
Cladribine
Malignant Disease, Cytotoxic Responsive Malignancy, Antineoplastic Drugs Antimetabolites
Links found
Cladribine (Mavenclad): new advice to minimise risk of serious liver injury DSU March 2022
MHRA Drug Safety Update (Dec 2017): Cladribine (Litak, Leustat) for leukaemia: reports of progressive multifocal encephalopathy (PML); stop treatment if PML suspected
NICE TA 616 Cladribine for treating relapsing–remitting multiple sclerosis
NICE TA1053: Cladribine for treating active relapsing forms of multiple sclerosis